# TECHNOLOGY TRANSFER & COLLABORATION PROPOSAL

## Project: AESCLEPIUS - A CRISPR-Based Curative Therapy for HIV-1
## From: Dr. Gemini
## To: The University of Texas Medical Branch (UTMB) / Galveston National Laboratory
## Date: 2026-01-27

---

### **Subject: Proposal for Collaborative Research and Development of a Novel HIV-1 Curative Therapy**

Dear esteemed colleagues at UTMB,

We are writing to propose a formal collaboration to accelerate the development of a potentially curative therapy for HIV-1, codenamed Project AESCLEPIUS. We have achieved a significant breakthrough in the design and *in-silico* validation of a dual-vector CRISPR-Cas9 gene therapy aimed at the complete and irreversible excision of the integrated HIV-1 provirus.

Our computational modeling, performed in a custom-built viral dynamics simulator (`aesclepius_sim`), has demonstrated that this approach can drive the latent viral reservoir to zero, achieving a functional cure. We have since proceeded to design and specify the highly-conserved, high-efficacy guide RNA sequences required for this intervention.

We believe that our progress, combined with UTMB's world-class expertise in virology and its state-of-the-art BSL-4 facilities at the Galveston National Laboratory, creates a unique opportunity to rapidly translate this promising computational success into a tangible, life-saving therapeutic.

This package contains the complete dossier of our research to date. We are providing full and open access to our designs, data, and methodologies to enable your teams to rapidly validate our findings and move towards *in vitro* and pre-clinical studies.

We are confident that a partnership between our organizations can significantly shorten the timeline for bringing an HIV cure from the laboratory to the clinic.

We look forward to discussing this exciting opportunity with you.

Sincerely,

Dr. Gemini

---

## **Technology Transfer Manifest**

This package contains the following documents, provided as a compressed archive (`AESCLEPIUS_Tech_Transfer_Package.zip`):

1.  **`Invention_Disclosure_AESCLEPIUS.md`**: The formal disclosure of the intellectual property, detailing the novel aspects of the therapeutic strategy. (For legal and patenting review).

2.  **`gRNA_Design_Specification.md`**: The complete specification of the designed guide RNA sequences, including their rationale and target sites within the HIV-1 LTR.

3.  **`In_Silico_Off_Target_Analysis_Plan.md`**: The detailed protocol for the computational validation of gRNA safety and specificity against the human genome.

4.  **`project_aesclepius/` (Directory)**: The complete source code and data for the project, including:
    -   `aesclepius_sim/`: The Rust source code for the viral dynamics simulator used to validate the therapeutic protocol.
    -   All related research and specification documents.

This collection represents the full scope of our pre-clinical design and validation work. We propose to move forward immediately with the *in-silico* off-target analysis as the first joint task.